Pasithea's PAS-004 Shrinks Skin Tumors in All 15 Evaluable Patients - Pasithea Therapeutics
TITLE: Pasithea Therapeutics Reports Positive Results for PAS-004 in Skin Tumor Study
Pasithea Therapeutics has announced significant clinical progress regarding its drug candidate PAS-004, following a presentation at the 2026 European Neurofibromatosis Conference. The biotechnology firm released data from its clinical trial, known as Study PAS-004-103 and registered under the identifier NCT06961565. This research focuses on the treatment of Neurofibromatosis type 1, which is frequently referred to by the medical community as NF1. The company reported that in a group of 15 evaluable patients, the drug successfully induced tumor shrinkage in every single participant. This unanimous response among the initial cohort marks a potential milestone for the development of the therapy.
Results for Evaluable Nf1 Patients
The study results specifically addressed the reduction of skin tumors in patients living with NF1. This rare genetic condition is categorized as progressive, meaning it generally advances and worsens as a patient ages. The root cause of the disorder is a mutation in the NF1 gene, which can be passed down through families as an inherited trait or occur spontaneously without a prior family history. One of the hallmark signs of the disease is the appearance of cutaneous neurofibromas, which are soft masses that form on the skin or just under the surface. The trial data indicates that PAS-004 was effective in reducing the size of these growths across the entire evaluable test group.
Risks of Plexiform Neurofibromas
Beyond the surface-level skin tumors, NF1 is associated with more complex internal growths. Pasithea noted that up to 50% of individuals diagnosed with NF1 will develop plexiform neurofibromas, often abbreviated as PN. Unlike the smaller cutaneous lumps, these tumors emerge along the nerve sheaths and can grow to significant sizes. The presence of PN represents a more severe stage of the condition, as these masses are linked to a variety of debilitating clinical complications. Because the disease is progressive, the management of these nerve-based tumors is a critical focus for medical researchers and patients alike.
Clinical Issues and Motor Dysfunction
The complications arising from plexiform neurofibromas extend far beyond aesthetic concerns. While disfigurement is a common result of these growths, the internal impact on bodily functions is often more severe. Patients frequently experience intense pain and motor dysfunction that can limit their physical mobility. In more critical instances, the tumors can lead to airway dysfunction, making breathing difficult, or cause significant visual impairment. Furthermore, the company highlighted that PN can interfere with the autonomic nervous system, leading to bladder or bowel dysfunction. By presenting these findings at the 2026 European Neurofibromatosis Conference, Pasithea continues to document how PAS-004 might mitigate these life-altering symptoms for the NF1 community.
Source: benzinga.com · 2026-11-13